ChemT Biotechnology Secures $4M Seed Round for AI Biomanufacturing Platform

ChemT Biotechnology, an AI-driven biotechnology company building the intelligence layer for biomanufacturing, has closed a US$4 million seed round led by Wavemaker Ventures to advance its AI platform for manufacturing advanced medicines. The total funding over 18 months comprises US$1 million in angel investment and the US$4 million seed round, with participation from SEEDS and other investors including Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.

At the core of the company is CelMo™, an AI-driven Virtual Cell platform trained on billions to trillions of proprietary biological sequencing reads. The platform is designed to simulate how cells respond to manufacturing conditions, genetic changes, and other stresses, providing a dynamic picture of how cell states shift throughout manufacturing. In CHO cells, the cell type most commonly used to manufacture antibodies and therapeutic proteins, CelMo™ has demonstrated a 50% increase in antibody output and a 40% reduction in production timelines.

ChemT's flagship small molecule product, Chemplify™, applies the same approach to T-cell manufacturing, a critical component of advanced cancer therapies. Chemplify™ has demonstrated 50% faster development, 3× scalability, 60% lower costs, and 10× higher cell expansion yield.

The financing will support the continued expansion of ChemT's AI and experimental infrastructure, advancement of its AI-designed molecular products toward GMP standards and regulatory readiness, scaling of commercial partnerships, and further development of CelMo™. Within roughly a year and a half of launch, the company has built commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies across the globe.

ChemT plans to expand the platform beyond CHO cells and T cells into other cellular systems, including stem cells, NK cells (Natural Killer cells, used in next-generation cancer immunotherapies), and HEK cells (Human Embroided Kidney cells, widely used in gene therapy and biologics production), enabling broader intelligent control across biomanufacturing workflows.

The co-founder and CEO stated that the financing validates the team, technology, and mission during a difficult funding environment for life sciences. The co-founder and President said CelMo™ is the cellular world model to understand what's happening inside cells and intervene intelligently, with the goal to help make advanced medicines easier to manufacture, scale, and deliver to patients worldwide.